Full Text View
Tabular View
No Study Results Posted
Related Studies
12-Week, Double-Blind, Placeob-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
This study has been completed.
Study NCT00456794   Information provided by Kyowa Hakko Kirin Pharma, Inc.

First Received on April 3, 2007.   Last Updated on June 22, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Additional conditions recognized in this trial
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Interventions listed in this trial
Istradefylline (KW-6002)
Additional drug interventions recognized in this trial
Istradefylline
Levodopa
More general drug interventions related to this trial
Adenosine A2 Receptor Antagonists
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Therapeutic Uses
Sponsors listed in this trial
Kyowa Hakko Kirin Pharma, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services